Heng Rui, a "Pharma Express" company, took the exclusive interest in PI3k inhibitors in China

February 9, 2021 / Medical Information At a Glance: HengRui took the exclusive interest in PI3k inhibitors in China; Xu Huabin, vice president of Human Fu Pharmaceuticals, resigned; and AstraZeneta's new crown vaccine was suspended in South Africa. Daily fresh medicine news, speed reading society and you pay attention to! Part1 Policy Brief Beijing for 10 consecutive days local zero new! Yesterday, three cases were cured and discharged from the hospital from 0:00 to 24:00 on February 8, and there were no new locally confirmed cases, suspected cases and asymptomatic infections in Beijing;
(CCTV News) A pharmaceutical company was suspended from production Gansu Provincial Drug Administration recently issued a notice that, in a drug supervision and inspection, found that Gansu Pu'ankang Pharmaceutical Co., Ltd. Chinese medicine tablet production does not meet the "Drug Production Quality Management Code", there is a risk of quality and safety risks.
in accordance with the provisions of Article 99, paragraph 3, of the Drug Administration Law of the People's Republic of China, the Drug Administration has decided to suspend the production and sale of Chinese medicine tablets of Gansu Pu'ankang Pharmaceutical Co., Ltd. from now on.
(Gansu Provincial Drug Administration) Wuhan anti-epidemic doctor Aifen: has been reported in real name Hubei Eyre Eye General Hospital february 9, Wuhan anti-epidemic doctor Ai fen in Eyre ophthalmology after the appearance of retinal separation from the right eye near blindness continues to ferment.
This morning, Aifen said in his personal microblog that on the afternoon of February 2, he submitted a report letter to the Medical Certificate Medical Management Department of Wuhan Health and Health Commission, "real name reporting the medical behavior violations of Hubei Eyre Eye Hospital."
report letter detailed the problems in the hospital's diagnosis and treatment process.
(Caixin) and cut the price again! Hebei nucleic acid 10 people mixed test down to 20 yuan 8, Hebei Province issued a notice, the medical institutions to carry out nucleic acid 5 people mixed test price, from 40 yuan to 30 yuan per person;
, it is clear that the province's public medical institutions can not charge the new coronavirus nucleic acid testing outpatient consultation fee.
(CCTV News) Hunan nucleic acid detection dropped to 80 yuan / person hybrid detection minimum 20 yuan / person February 9, Hunan Provincial Development and Reform Commission official website issued "on the adjustment of the new coronavirus nucleic acid testing fee standard notice" said that the new coronavirus nucleic acid testing fee standard adjusted to 80 yuan / person.
According to the needs of the epidemic, large-scale population screening, in accordance with the relevant technical requirements and standards to implement mixed testing, 5 samples mixed testing, the fee is 30 yuan / person;
this Notice will be effective from 10 February 2021.
(Hunan Provincial Development and Reform Commission) Part2 by the observer Fu Pharmaceutical Vice President Xu Huabin resigned on February 9, People's Fu Pharmaceuticals issued a notice that the company's board of directors recently received the company's vice president Mr. Xu Huabin's written resignation report, Mr. Xu Huabin for personal reasons to apply to resign as vice president of the company, resignation report from the date of service to the company's board of directors, after his resignation will no longer hold any position in the company.
(People's Fu Pharmaceuticals Announcement) Hengrui took the exclusive interest in PI3k inhibitors in China on February 8, Hengrui announced that Hengrui intends to self-financing 20 million U.S. dollars to subscribe for a 6.67 percent stake in Li Pharmaceuticals.
agreement was reached with Yuli Pharmaceuticals to grant Hengrui Pharmaceuticals a joint development interest in the Greater China region of PIPERIL inhibitor Linperlisib, as well as an exclusive exclusive commercialization interest in exorcism.
(Hengrui Pharmaceutical Announcement) National Pharmaceutical Oral Completed A round of financing February 9, arterial network was informed at the first time, China Pharmaceutical Oral announced the completion of A round of financing.
this round of financing by Huaxing Capital's Huaxing New Economic Fund, Detong Capital and Investment, Huaxing Capital as the current round of financing of the exclusive financial adviser.
(Arterial Network) Yuan heart technology completed 3 billion yuan E round financing artery network was informed the first time, February 9, Yuan heart technology officially announced the completion of 3 billion yuan E round financing, this round is following the completion of D round financing in June 2020 Six months later, another round of financing, led by Sequoia Capital China Fund and Tencent, CITIC Securities, COFKIN Capital, OrbiMed, Qiming Ventures, Yan Capital, Gopher Assets, Efonda Fund and other investment, index capital as the exclusive financial adviser.
(Arterial Network) Changmugu completed 120 million yuan Pre-B round financing artery network was informed the first time, Changmugu recently completed 120 million yuan Pre-B round of financing, this round of financing by Yuanyuan origin lead investment, Yuansheng Ventures, Lenovo Star, Shenzhen Xintron co-investment, Kaiyu Capital as a financial adviser.
this round of financing will be mainly used to accelerate the development and clinical trials of orthopaedic surgical robots, accelerate the marketing of orthopaedic artificial intelligence products, and prepare for global registration and marketing.
(Arterial Network) Model Biotechnology completed the first round of 10 million-level financing arterial network was informed that in early 2021, Model Biotech successfully completed the first round of 10 million-level RMB financing delivery, the financing agreement was signed at the end of 2020.
round of financing is jointly funded by Dow Investment and Johnson Capital.
(Arterial Network) Shandong Kangsheng Medical completed more than RMB C round financing artery network was informed the first time, recently Kangsheng Medical announced the completion of more than RMB C round of financing, this round of financing led by Tongcheng Weiye, Oriental Fuhai,Spring Development, Shanghai Yuhan, Suzhou for Kang and other investment.
This financing is another round of strategic financing after the B-round financing of Shenzhen Ventures in January 2020, which is mainly used for the research and development, production and sales of vertebral orthopaedic mirrors, artificial joint orthopaedic supplies and sports medicine products.
(Arterial Network) Part3 Drug News Pakistani health officials: Consino vaccine phase III clinical trial effective rate of 74.8% Pakistan's Special Assistant to the Prime Minister for National Health Affairs Fesso Sultan announced on February 8, local time, The Chinese Chen Wei academician team and An interim analysis of phase III clinical trials conducted in Pakistan by Kwesha, a new coronavirus vector developed in collaboration with Consino, showed that after 28 days of single-shot vaccination, the protective effect of severe neo-corona pneumonia was 100% and the overall protective effect was 74.8%.
no serious adverse reactions associated with the vaccine have occurred.
(Sina Pharmaceutical News) Cinda Bio announced the new progress of IBI310 Joint Dabershu III clinical research recently, Cinda Bio announced that IBI310 Joint PD-1 inhibitor Daboshu for the treatment of first-line advanced hepatocellular carcinoma, a randomized, open, controlled multi-center III key clinical study has completed the first patient group and administration.
(Xinhua) -- The final clinical results of Phase 3 of Jansen's prostate cancer therapy were released on February 9, and Johnson and Johnson's Jansen announced the final results of its prostate cancer therapy Erleada in Phase 3 clinical trial TITAN.
trial results showed that the addition of Erleada to androgen deprivation therapy in patients with metastatic descessive prostate cancer significantly improved the overall survival of patients compared to placebo.
Erleada plus ADT reduced the risk of death by 35% compared to ADT therapy.
(Drug Mingkangde) AVROBIO announced on February 9 that the first patients with farbria who received the insotrophic lyviral gene therapy designed by its plato technology platform had a 100% reduction in toxic substrates in kidney biopsies after 12 months of treatment.
reduction of renal toxicity substrates is the primary therapeutic endpoint of this Phase 2 clinical trial, which has previously been used by the FDA to evaluate and approve treatments for Fabri disease.
(Pharmaceutical Mingkangde) Genesis and Affibody obtained fda applications for Phase II clinical trials of ibokibeep's Phase II clinical IND Ontones on February 9th, and the FDA approved its candidate drug, izokibep, for the treatment of severe spina blingitis.
Izokibep was jointly developed by Genesis and its partner, Swedish Affibody AB.
the two sides to cooperate in multi-center clinical trials of five autoimmune diseases around the world.
(THE Associated Press) In response to the critical new coronary gene variant Pfizer/BioNTech vaccine maintenance and stability Today, Pfizer and BioNTech jointly announced that an in-body study showed that serums of individuals vaccinated against the new crown vaccine BNT162b2 still have the ability to mediate key genes carried in a variety of recent new coronary mutant strains.
the study, conducted by Pfizer and researchers at the University of Texas School of Medicine, was published in the journal Nature.
(Amineconde) AstraZenecom's new crown vaccine has been suspended in South Africa, foreign media reported that South Africa has postponed the Promotion of the AstraZeneta/Oxford University COVID-19 vaccine, because data show that the vaccine infected with the South African variant B.1.351 virus in mild patients "only provide minimal protection."
the data was released by the Wits Vaccine and Infectious Disease Analysis Research Unit, which is conducting COVID-19 vaccine trials in South Africa.
data have yet to be peer-reviewed.
(Sina Pharmaceutical News) Breyanzi CAR-T cell therapy has been approved by the FDA, the FDA approved the CD19 CAR-T cell therapy Breyanzi for the treatment of recurrence or refractic large B cell lymphoma adult patients treated in two or more systemic treatments.
breyanzi therapy was approved, relying primarily on efficacy and safety data from transCEND NHL 001 clinical trials.
(Sina Pharmaceutical News) Huahai Pharmaceuticals: The preparation product chloropropylate external solution was approved by the U.S. FDA recently, Huahai Pharmaceuticals received a notice from the U.S. FDA, the company to the U.S. FDA declared a new drug for chloropropylate external solution has been approved.
the external solution of chlorpyrine acrylic is mainly used to treat itching, redness and swelling caused by certain skin conditions.
a solution for the use of chlorpyric acid in the united States was developed by Galderma.
(Huahai Pharmaceuticals Announcement) ViiV's new pioneering attachment inhibitor Rukobia was approved by the European Union on February 8th, and ViiV Healthcare announced that Rukobia's 600mg slow-release tablet had been approved for use in combination with other antiretroviral therapies to treat adults with multidrive resistance HIV-1, which does not constitute an inhibitory antiviral programme.
(Sina Pharmaceutical News) Microcore Biology: Theo Ronnie capsule approved clinical trial February 9, microcore bio-announcement, the company recently received NMPA's new drug clinical trial application "acceptance notice", the product name is Theo Ronnie capsule.
is a small molecule anti-tumor original innovative drug that selectively inhibits several kinase targets such as Aurora B, CSF1R and VEGFR/PDGFR/c-Kit.
(Microcore Biological Announcement) Luoxin Pharmaceuticals: Hedara non-tablets were approved for market on February 8, Luoxin Pharmaceuticals announced that its subsidiary Shandong Luoxin recently received the approval of NMPA issued the Tadara non-tablet "Drug Registration Certificate."
is a selective, reversible phosphate dylsterase 5 inhibitor.
is intended to address erectile dysfunction in men.
(Rohingya Pharmaceuticals Announcement) Kumasi Ping slow release tablets obtained the "Drug Production License" february 9, Kyuszhou Pharmaceuticals announced that the subsidiary Kyusho Biopharmaceuticals received the Zhejiang Provincial Drug Administration issued a "drug production license", agreed to Guangzhou Bosin Control and Release Pharmaceutical Co., Ltd. as a entrusted production enterprise to produce Camasi ping slow release tablets.
(Kyuszhou Pharmaceuticals Announcement) Ted Pharmaceutical Pari osteoporine injection approved drug registration certificate recently, Ted Pharmaceuticals announced that its self-developed Paritol injection was officially awarded the drug registration certificate issued by NMPA.
Pali osteoporosisol is the latest generation of selective vitamin D-receiving excitants, combined with vitamin D-receiving to effectively reduce thyroid side gland hormones, through hemodialysis pathopathy, used to treat patients receiving hemodialysis of chronic renal failure of secondary thyroid hypergenetic hypergenicity.
(Sina Pharmaceutical News) Tian Pharmaceuticals sodium bromfinate eye drops to obtain the drug registration certificate February 9, Tian Pharmaceuticals announced that the subsidiary Jinyao Pharmaceuticals recently received NMPA approved the issuance of the "drug registration certificate" on sodium bromfinate eye drops.
sodium bromofenate eye drops are a new type of nonsteroidal anti-inflammatory drugs, mainly used in the treatment of inflammatory diseases in the eye, such as conjunctivitis, scleitis, postoperative inflammation and so on.
(Tian Pharmaceuticals Announcement)